

NASDAQ: CRME **TSX: COM**

VANCOUVER, Sept. 16, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: [CRME](#) / TSX: COM) today announced completion of the transfer of commercialization responsibility for BRINAVESS™ (vernakalant IV) in the European Union (EU) from its former partner, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co (Merck). Cardiome has begun supplying BRINAVESS under its own trade dress and transfer of the post-marketing study for BRINAVESS is now complete. Cardiome will continue to market BRINAVESS through its direct sales force in key European markets and through distribution partnerships in others, and recognize revenues for the product worldwide.

"The completion of the transfer of commercialization responsibility to Cardiome today is an exciting and transformational turning point in the company's history," said William Hunter, M.D., Cardiome's chief executive officer. "We have taken BRINAVESS from our research lab, moved it forward through clinical development, and now we have the responsibility for commercialization of the drug in order to provide patients suffering from atrial fibrillation a rapid and convenient treatment option to restore normal sinus rhythm. We thank Merck for its cooperation over the past year in the transfer of the BRINAVESS commercialization responsibilities back to Cardiome."

About Cardiome Pharma Corp. Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients around the world. Cardiome has one marketed product, BRINAVESS™ (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com

Forward-Looking Statement Disclaimer Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the remainder of 2013 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States

,

Canada

,

Europe

, and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to expand commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this presentation to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; intellectual property matters, including the unenforceability or loss of patent protection resulting from third-party challenges to our patents; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; and any other factors described in detail in our filings with the Securities and Exchange Commission available at

www.sec.gov

and the Canadian securities regulatory authorities at

www.sedar.com

. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on

Cardiome Completes Transfer Of Commercialization Responsibility For Brinavess™ In The EU

Written by Australian Business

such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

SOURCE Cardiome Pharma Corp.